CClinicalTrials.gg
Status unknownNCT03192098DILATEUpdated Jun 19, 2017

Progressive Esophageal Dilation for Benign Strictures: a Randomized Controlled Trial

An interventional study of Savary bougie dilation in Benign Esophageal Stricture, sponsored by Radboud University Medical Center. Status unknown at 1 site in Netherlands. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2017-06-19.

Sponsored by Radboud University Medical Center · Not applicable, Interventional, and Treatment

The sponsor has not verified this record recently (last verified May 2017), so the status shown — last known as Recruiting — may be out of date.
Phase
Not applicable
Study type
Interventional
Enrollment
80
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

A randomized controlled prospective clinical trial assessing the efficacy and safety of progressive esophageal dilation compared to conservative esophageal dilation in patients with severe benign esophageal strictures.

Read the detailed description

A randomized controlled prospective clinical trial assessing the efficacy and safety of progressive esophageal dilation (up to 6mm) compared to esophageal dilation according to the rule-of-3 in patients with severe benign esophageal strictures. Patients will be followed up for 6 months. When recurrent dysphagia occurs within 6 months the patients will be dilated according to the previously allocated strategy.

02

Conditions studied

  • Benign Esophageal Stricture
03

In context

Esophageal Stenosis

50 studies on the registry are indexed under Esophageal Stenosis; 11 are open to participants now.

This study's planned enrollment of 80 is above the median of 24 across 41 interventional studies indexed under Esophageal Stenosis.

Browse Esophageal Stenosis studies →

Lead sponsor

Radboud University Medical Center is the lead sponsor of 959 studies on the registry; 134 are open to participants now.

Of its 6 completed or terminated interventional studies of FDA-regulated products, 0 (0%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  • Dysphagia due to benign esophageal stricture (e.g. surgery, radiation therapy, caustic ingestion, peptic injury, photodynamic therapy) requiring esophageal dilation
  • Requiring first esophageal dilation for dysphagia due to a severe benign esophageal stricture with no patency for standard upper endoscope (9-10mm diameter)
  • No history of esophageal endoscopic dilations for benign strictures the past 6 months
  • Dysphagia for solid, semisolid or liquid food (dysphagia score ≥ 2 [Ogilvie]16, and dysphagia score ≤ 21 [Dakkak and Bennett]19, see appendix)
  • Written informed consent

Exclusion criteria

Exclusion Criteria:

  • Patient \< 18 years old
  • Patient is unwilling or unable to sign and date the informed consent
  • Patient is unwilling or unable to comply with the follow-up schedule
  • Patient is unable to understand informed consent and fill in the questionnaires due to a language barrier
  • Patient is pregnant, breast-feeding, or planning to become pregnant in the next 12 month
  • Patient is simultaneously participating in another drug or device study or the patient has completed the follow-up phase for the primary objective of any previous study less than 30 days prior to enrollment in this study
  • Previous esophageal dilation for benign stricture within the past 6 months
  • Patient with a life expectancy \< 12 months
  • Patient with a known eosinophilic esophagitis or motility disorder (such as achalasia)
  • Patients with a known malignant esophageal stricture
  • Patients with a benign stricture due to a previous performed laryngectomy

Endoscopic exclusion criteria:

  • Benign strictures in the upper part of the esophagus too close to the cricopharyngeal muscle (for the purpose of this protocol, within 1½ cm of the upper esophageal sphincter)
  • Patients with stricture ≥ 10 cm in length
  • Patients with an active esophageal perforation, leak, fistula, or varices
  • Stricture within necrotic chronically bleeding tumors
  • Highly suspected esophageal malignancy
  • Stricture within polypoid lesions
  • Known or strongly suspected dysmotility esophageal disorder
  • Patient with high suspicion for an esophageal web, Schatzki ring, eosinophilic esophagitis, or motility disorder (such as achalasia)
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Participant)
Enrollment
80 participants (estimated)

Study arms

  • Experimental
    Progressive

    Patients will be dilated \> 3mm and can be dilated up to 6mm in diameter

    Device: Savary bougie dilation

  • Active comparator
    Conservative (rule-of-3)

    Patients will be dilated according to the rule-of-3 (i.e. dilation of no more than 3mm in diameter)

    Device: Savary bougie dilation

Interventions

  • DeviceSavary bougie dilation

    Patients will be dilated with the use of the Savary bougienage device

06

What researchers measure

Primary outcomes

  1. Total number of dilation procedures within 6 months of follow-up

    Total number of dilation procedures within 6 months of follow-up

    Time frame: 6 months

  2. Total number of dilation procedures during first dilation session to 16-18mm

    Total number of dilation procedures during first dilation session to 16-18mm

    Time frame: 1 month

Secondary outcomes

  1. Dysphagia free patients

    Number of patients remaining dysphagia free within 6 months after dilation to 16-18mm

    Time frame: 6 months

  2. Timeframe first dilation session

    Time from first dilation session to dilation of 16-18mm

    Time frame: 1 month

  3. Dysphagia free time period

    Time to dilation of recurrent stricture after initial dilation to 16-18mm

    Time frame: 6 months

  4. Incidence of treatment-related mortality (serious) adverse events (safety)

    Incidence of treatment-related mortality (serious) adverse events (safety)

    Time frame: 7 months

  5. Quality of Life

    SF-36, disease specific questionnaire

    Time frame: 6 months

  6. Medical costs

    Direct medicals costs: procedures, secondary interventions

    Time frame: 7 months

07

Study locations

1 of 1 sites recruiting
  • Radboudumc
    Nijmegen, Gelderland 6500HB, Netherlands
    Recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Jun 19, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03192098
Lead sponsor
Radboud University Medical Center
Responsible party
Sponsor
First posted
Jun 19, 2017
Start date
May 1, 2017
Primary completion
Nov 1, 2018 (estimated)
Completion
May 1, 2019 (estimated)
Last update
Jun 19, 2017

Study contacts

Bram Vermeulen, Drs.
Contact
bram.vermeulen@radboudumc.nl
0611079557 ext. +31
Peter Siersema, Dr.
Contact
peter.siersema@radboudumc.nl
06 547 84 967 ext. +31

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in May 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion